In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Identification of RAF1 gene mutations in Hungarian patients with hypertrophic cardiomyopathy

Session Poster Session 3

Speaker Lidia Hategan

Congress : Heart Failure 2019

  • Topic : basic science
  • Sub-topic : Basic Science - Cardiac Diseases: Cardiac Hypertrophy
  • Session type : Poster Session
  • FP Number : P1882

Authors : L Hategan (Szeged,HU), M Katona (Szeged,HU), A Tringer (Szeged,HU), B Csanyi (Szeged,HU), J Borbas (Szeged,HU), V Nagy (Szeged,HU), Z Hegedus (Szeged,HU), I Nagy (Morahalom,HU), T Forster (Szeged,HU), R Sepp (Szeged,HU)

L Hategan1 , M Katona2 , A Tringer1 , B Csanyi1 , J Borbas1 , V Nagy1 , Z Hegedus3 , I Nagy4 , T Forster1 , R Sepp1 , 1Biological Research Centre of Szeged, 2nd Department of Internal Medicine and Cardiological Center - Szeged - Hungary , 2University of Szeged, Department of Pediatrics - Szeged - Hungary , 3Institute of Biophysics, Bioinformatics Group, Biological Research Center - Szeged - Hungary , 4Seqomics Biotechnology Ltd - Morahalom - Hungary ,


Noonan syndrome (NS) belongs to RASopathies and is an autosomal dominant genetic disorder characterized by distinct facial features, short stature, congenital heart defects and developmental delays. However, in many cases it occurs de novo. Pathogenic variants in several RasMAPK pathway genes have been found to contribute to the phenotype, the most prevalent gene (50% of cases) being PTPN11. The rest of the affected individuals harbour mutations in other genes among which the proto-oncogene RAF1 is quite rare (only 3-17% of cases). RAF1 encodes a MAP3K that plays an essential role in cell division, differentiation and apoptosis. Mutations in this gene are associated with Noonan sy. 5 and Leopard sy. 2. Moreover, the majority of patients with RAF1 pathogenic variants manifest cardiac involvements, especially HCM (hypertrophic cardiomyopathy).

The goal of the study was genetic screening for RAF1 mutations in a Hungarian HCM cohort.

We screened 133 HCM patients (81 men, 52 women, average age: 45±15 years) using Next Generation Sequencing. RAF1 gene was also included in the 103 HCM genes panel.

Out of 133 HCM patients included in the study, 2 carried rare pathogenic variants in RAF1 gene that are indicative of NS: p.Ser257Leu in exon 7, and p.Leu633Val in exon 18. The first missense mutation was identified in a 1 year old girl and it’s clustered in the CR2 domain of the RAF1 protein known for its regulatory role. Several reports in the literature describe this mutation as highly pathogenic. The second mutation was identified in a newborn boy without a typical manifestation of NS but with a complex cardiac phenotype including severe obstructive hypertrophic cardiomyopathy, pulmonary stenosis and atrial septal defect. Family screening revealed that the mutation occurred de novo, further reinforcing its pathogenicity.

RAF1 pathogenic gene variants are rare cause of typical HCM and may be suspected in syndromic disease or with complex cardiac phenotypes.

Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are